ICU Medical (NASDAQ:ICUI) updated its FY 2019 earnings guidance on Wednesday. The company provided earnings per share guidance of $7.55-8.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.30. ICU Medical also updated its FY19 guidance to $7.55-8.15 EPS.
Several research analysts have commented on the company. Raymond James downgraded ICU Medical from a strong-buy rating to an outperform rating in a research note on Thursday. Zacks Investment Research downgraded ICU Medical from a buy rating to a hold rating in a research note on Thursday, July 25th. ValuEngine downgraded ICU Medical from a hold rating to a sell rating in a research note on Thursday. TheStreet upgraded ICU Medical from a c+ rating to a b rating in a research note on Friday, May 10th. Finally, BidaskClub upgraded ICU Medical from a hold rating to a buy rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. ICU Medical presently has an average rating of Hold and an average price target of $290.50.
NASDAQ ICUI traded up $2.93 during trading hours on Friday, hitting $166.89. The company had a trading volume of 621,432 shares, compared to its average volume of 132,178. ICU Medical has a 52 week low of $160.00 and a 52 week high of $321.70. The company’s 50 day moving average is $247.21. The company has a market capitalization of $5.06 billion, a price-to-earnings ratio of 21.65 and a beta of 0.81.
ICU Medical (NASDAQ:ICUI) last issued its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.99 EPS for the quarter, topping the consensus estimate of $1.86 by $0.13. ICU Medical had a return on equity of 12.53% and a net margin of 3.56%. The business had revenue of $312.30 million during the quarter, compared to the consensus estimate of $315.47 million. During the same quarter last year, the company earned $2.69 EPS. The firm’s revenue was down 13.4% compared to the same quarter last year. As a group, equities research analysts anticipate that ICU Medical will post 8.55 earnings per share for the current year.
In other news, insider Kevin J. Mcgrody sold 7,344 shares of ICU Medical stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $231.68, for a total transaction of $1,701,457.92. Following the completion of the sale, the insider now owns 7,574 shares in the company, valued at approximately $1,754,744.32. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Christian B. Voigtlander sold 5,348 shares of ICU Medical stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $227.59, for a total value of $1,217,151.32. Following the sale, the chief operating officer now owns 4,732 shares of the company’s stock, valued at approximately $1,076,955.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,931 shares of company stock valued at $9,228,056. 11.40% of the stock is owned by corporate insiders.
About ICU Medical
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Further Reading: Put Option Volume
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.